Perspective Therapeutics (CATX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Voting matters and shareholder proposals
Six director nominees are up for election, with the board recommending a vote for all nominees.
Shareholders are asked to ratify WithumSmith + Brown, PC as the independent auditor for the fiscal year ending December 31, 2026.
Advisory vote on the frequency of say-on-pay votes for executive compensation is included, with 'Year' as the recommended frequency.
Board of directors and corporate governance
The slate of director nominees includes Lori A. Woods, Heidi Henson, Robert Froman Williamson III, Frank Morich, Johan (Thijs) Spoor, and Maya Martinez-Davis.
Executive compensation and say-on-pay
Shareholders are invited to provide a non-binding advisory vote on how often they wish to vote on executive compensation, with annual votes recommended.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Perspective Therapeutics
- Net loss increased to $26.2M as R&D ramped up, with cash rising to $271M after equity raise.CATX
Q1 202611 May 2026 - Board recommends annual say-on-pay votes and highlights recent governance improvements.CATX
Proxy filing16 Apr 2026 - Clinical pipeline advances with strong safety, efficacy, and funding to support growth into 2027.CATX
Q4 202516 Mar 2026 - Lead-based radiopharmaceuticals advance with strong clinical progress and robust infrastructure.CATX
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Strong clinical data, innovative technology, and pipeline expansion drive growth prospects.CATX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Strong clinical results, scalable manufacturing, and robust pipeline drive growth prospects.CATX
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Multiple radiopharma programs advance with key data and trial milestones expected in the next year.CATX
UBS Global Healthcare Conference14 Jan 2026 - Lead-212 radiopharma pipeline advances with strong early data, networked supply, and funding to 2026.CATX
Stifel 2024 Healthcare Conference13 Jan 2026 - Strong early efficacy and safety in radioligand pipeline, with key data and trials ahead.CATX
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026